CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗急性髓系白血病
英文原题：Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia.
查看英文原题
Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
靶向CD19的嵌合抗原受体（CAR）T细胞已显著改善B细胞恶性肿瘤的结局；然而，这一成功尚未扩展至急性髓系白血病（AML）等髓系恶性肿瘤。AML中CAR-T 疗法发展的主要障碍包括难以识别对髓系白血病干细胞特异、同时不损伤健康造血干祖细胞（HSPCs）的合适靶抗原。在此，我们讨论CAR-T 细胞疗法在AML中的现状，重点介绍近期临床转化进展与局限。我们还讨论CAR-T 疗法开发的新方法，以及在增强抗白血病活性同时尽量减少对健康细胞毒性的潜在策略，以使CAR-T 细胞疗法成为AML患者的可行选择。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cells targeting CD19 have drastically improved the outcomes of B-cell malignancies; however, the success has not yet extended to myeloid malignancies such as acute myeloid leukemia (AML). Main impediments in the development of CAR T therapy in AML include difficulty in identifying appropriate target antigens that are specific to myeloid leukemia stem cells while sparing the healthy hematopoietic stem progenitor cells (HSPCs).
Herein, we discuss the current state of CAR T-cell therapy in AML, highlighting recent progress and limitations in clinical translation.
We also discuss novel approaches in CAR T therapy development and potential strategies to enhance anti-leukemic activity while minimizing toxicity to heathy cells to make CAR T-cell therapy a viable option for patients with AML.
论文信息
- 作者
- Bi X、Hsu J、Gergis M、Yang Y、Yi D、Gergis U
- 单位
- Thomas Jefferson University Sidney Kimmel Medical College.
- 期刊
- Hematology/oncology and stem cell therapy2022 Dec 15
- 原文标识
- PubMed 36537909 · DOI 10.56875/2589-0646.1062